Literature DB >> 3620309

Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.

K R Huber, E P Mayer, D F Mitchell, J Roberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3620309      PMCID： PMC2002038          DOI： 10.1038/bjc.1987.133

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  16 in total

1.  Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7Z.

Authors:  J Roberts
Journal:  J Biol Chem       Date:  1976-04-10       Impact factor: 5.157

2.  L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.

Authors:  H N Jayaram; D A Cooney; J A Ryan; G Neil; R L Dion; V H Bono
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

3.  Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases.

Authors:  F A Schmid; J Roberts
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

4.  The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry.

Authors:  J T Thornthwaite; L M Allen
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-08

5.  Phase I study of 6-diazo-5-oxo-L-norleucine (DON).

Authors:  R B Sklaroff; E S Casper; G B Magill; C W Young
Journal:  Cancer Treat Rep       Date:  1980

6.  Preparation of tissues for DNA flow cytometric analysis.

Authors:  J T Thornthwaite; E V Sugarbaker; W J Temple
Journal:  Cytometry       Date:  1980-11

7.  In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma.

Authors:  T Aoki; J Sebolt; G Weber
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

8.  Biochemical pharmacology of acivicin in rat hepatoma cells.

Authors:  M S Lui; H Kizaki; G Weber
Journal:  Biochem Pharmacol       Date:  1982-11-01       Impact factor: 5.858

9.  Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.

Authors:  H Rosenfeld; J Roberts
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

10.  Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.

Authors:  J S Holcenberg
Journal:  Cancer Treat Rep       Date:  1979-06
View more
  6 in total

1.  The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Liang Zhao; Ying Wu; Vijayabhaskar Veeravalli; Jesse Alt; Joanna Marie H Aguilar; Ranjeet P Dash; Jenny Lam; Lukáš Tenora; Chabely Rodriguez; Michael T Nedelcovych; Cory Brayton; Pavel Majer; Jaishri O Blakeley; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

2.  SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.

Authors:  Mohamed Hassanein; Megan D Hoeksema; Masakazu Shiota; Jun Qian; Bradford K Harris; Heidi Chen; Jonathan E Clark; William E Alborn; Rosana Eisenberg; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

Review 3.  Altered glutamine metabolism and therapeutic opportunities for lung cancer.

Authors:  Amr Mohamed; Xingming Deng; Fadlo R Khuri; Taofeek K Owonikoko
Journal:  Clin Lung Cancer       Date:  2013-11-13       Impact factor: 4.785

4.  Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.

Authors:  Mohamed Hassanein; Jun Qian; Megan D Hoeksema; Jing Wang; Marie Jacobovitz; Xiangming Ji; Fredrick T Harris; Bradford K Harris; Kelli L Boyd; Heidi Chen; Rosana Eisenberg; Pierre P Massion
Journal:  Int J Cancer       Date:  2015-05-06       Impact factor: 7.396

Review 5.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 6.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.